Loading clinical trials...
Loading clinical trials...
This purpose of this study is to determine if bosutinib reduces the rate of kidney enlargement in subjects with autosomal dominant polycystic kidney disease (ADPKD) entering the study with a total kid...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT04534985 · Polycystic Kidney, Autosomal Dominant
NCT01559363 · Polycystic Kidney, Autosomal Dominant
NCT02656017 · Polycystic Kidney, Autosomal Dominant
NCT03342742 · Polycystic Kidney, Autosomal Dominant
NCT02903511 · Polycystic Kidney, Autosomal Dominant
Southwest Kidney Institute, PLC
Phoenix, Arizona
Southwest Clinical Research Institute, LLC
Tempe, Arizona
Southwest Kidney Institute, PLC
Tempe, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions